Amid rising demand for GLP-1-based weight loss drugs, India’s drug regulator, Drugs Controller General of India, has stepped up monitoring of their distribution and sale to curb misuse and ensure patient safety.
Crackdown on Unauthorised Sales and Misleading Promotion
Regulatory authorities have intensified action against:
- Unauthorised sale of GLP-1 drugs
- Misleading advertisements and surrogate promotions
- Off-label use without medical supervision
The move comes as several generic versions of these drugs enter the Indian market, raising concerns over their availability through retail pharmacies, online platforms, wholesalers, and wellness clinics.
Health Risks Without Medical Supervision
Experts have warned that the use of GLP-1 drugs without proper medical guidance can lead to serious side effects and health complications.
In response, the regulator, in coordination with state drug controllers, has initiated targeted measures to address irregularities in the pharmaceutical supply chain.
Advisory Issued to Drug Manufacturers
On March 10, 2026, authorities issued a comprehensive advisory to drug manufacturers, clearly prohibiting:
- Surrogate advertising
- Indirect promotional activities
The aim is to prevent misleading consumers and discourage inappropriate or off-label usage.
Nationwide Inspections and Enforcement Action
In recent weeks, enforcement agencies have conducted audits and inspections of 49 entities, including:
- Online pharmacy warehouses
- Drug wholesalers
- Retail pharmacies
- Wellness and slimming clinics
These inspections focused on identifying violations such as:
- Unauthorized drug sales
- Improper prescription practices
- Misleading marketing
Entities found violating norms have been issued notices, with further action likely.
Strict Prescription Guidelines
Regulators clarified that GLP-1 drugs in India can only be prescribed by:
- Endocrinologists
- Internal medicine specialists
- Cardiologists (in specific cases)
Patients have been advised to use these medications only under qualified medical supervision.
More Stringent Action Ahead
Authorities have reiterated that patient safety remains the top priority and warned that stricter enforcement measures—including:
- License cancellation
- Financial penalties
- Legal action
will be taken against violators in the coming weeks.
